Objectives: The optimal duration of antibiotic therapy in patients with uncomplicated pneumonia may be shorter than that recommended in the current guidelines. A shorter duration will probably also lead to a cost reduction. This study evaluates the costs associated with 3 versus 8 day antibiotic therapy and subsequent follow-up in patients hospitalized with mild-to-moderate -severe community-acquired pneumonia.
Introduction
Community-acquired pneumonia (CAP) affects 5 to 11 cases per 1000 adults per year in Western countries, of whom 22 -42% are admitted to the hospital. 1 The total costs of care for hospitalized patients with respiratory tract infections (including CAP) are generated more by healthcare utilization rather than by the use of antibiotics. 2 Inpatient care in general accounts for over 90% of the costs of managing CAP. Current treatment guidelines developed by the British Thoracic Society for patients with CAP managed in the community and most of those admitted to hospital with non-severe and uncomplicated pneumonia recommend treatment with appropriate antibiotics for 7 days, whereas for patients with severe microbiologically undefined pneumonia, 10 days of treatment is proposed. 1 Thereby amoxicillin is the preferred antibiotic agent, but for patients who are hypersensitive to penicillins, a macrolide (erythromycin or clarithromycin) can be used as an alternative. Differences in treatment recommendations across countries are only partially explained by geographical variation in the distribution and antibiotic susceptibility of pathogens responsible; substantial variation reflects local custom and practice rather than robust scientific evidence. 1 The clinical effectiveness and economic efficiency of antimicrobial treatment strategies for CAP could be improved in several ways. One way to reduce antibiotic consumption is to improve antibiotic prescribing practices, refraining from prescription whenever there is no clear indication, such as in viral infections. A review of such interventions in primary care showed the potential for such improvements but stressed the multifaceted and multilevel character of the problem. 3 Efficiency gains can also be expected from strategies specifically aiming at a reduction in length of hospital stay, such as transitional therapy, converting from intravenous to oral antibiotics. The expected cost reductions result predominantly from a shortened length of hospital stay, as patients can complete therapy at home. In addition, a reduction in nursing time for preparation and administration of intravenous formulae as well as a reduction in nosocomial infections through the use of intravenous catheters can bring down the costs of treatment. 4 Another option to improve efficiency could be to limit the duration of therapy in those patients in whom antibiotic therapy is indicated. Scientific evidence supporting the appropriateness for the recommended duration (7-10 days) is limited. Two older studies have suggested that shorter durations may be justified, 5, 6 but these results have not been confirmed in more recent studies that meet today's standards of conducting and reporting clinical trials. 7 If comparable clinical results in terms of recovery and eradication rates can be obtained with a substantially shorter duration of therapy, a reduction in antibiotic consumption for this common illness can be obtained. From a societal perspective, the economic consequences of shorter duration of therapy are not immediately evident. On the one hand, a cost reduction can be expected, as hospital stay is at least partially driven by the fact a patient is still on therapy, and shorter treatment regimens may allow earlier discharge and thus shorten the length of hospital stay. It is unclear to what extent a reduction in the duration of antibiotic treatment actually reduces the duration of inpatient care. On the other hand, a shorter duration of therapy may also be associated with a substitution of resource consumption, by introducing a shift from secondary inpatient care to outpatient care and primary healthcare providers. This could be due to slower resolution or even recurrence of symptoms, resulting in more frequent visits to general practitioners. Indirectly, this may also incur productivity losses associated with the absence from work. Consequently, reduction in inpatient resource utilization is likely to result in an increased efficiency for the healthcare system (medical costs), but may as well be beneficial to the patient or to a society as a whole (non-medical or indirect costs).
In a recently conducted randomized, double-blind, placebocontrolled, multicentre trial, we evaluated whether a shorter duration of antibiotic therapy of CAP is sufficient in hospitalized patients with mild-to-moderate -severe CAP who have substantially improved after 72 h of antibiotic therapy. 8 Our findings demonstrated that 3 days of amoxicillin treatment is not inferior to 8 days of treatment in terms of symptom resolution and clinical recovery. We also investigated whether a shorter duration of therapy reduces resource utilization and associated healthcare and societal costs and whether or not a substitution effect offsets such efficiency gains, in terms of reduced length of hospital stay, and societal benefits, in terms of reduced antibiotic consumption, the development of resistance, as well as productivity loss. In this paper, we report the economic evaluation, in which costs during hospital admission and follow-up until 28 days after randomization to 3 day antibiotic treatment or (standard) 8 day therapy were compared from a societal perspective.
Patients and methods
Data were collected during a prospective double-blinded randomized controlled trial (RCT), designed to compare the effectiveness of short (3 days) and standard (8 days) antibiotic therapy in hospitalized adult patients with mild-to-moderatesevere CAP. The study protocol was reviewed and approved by the Institutional Review Boards of all participating hospitals. All eligible patients gave written informed consent. Further details on the RCT can be found elsewhere. 8 Assuming that short and standard durations are equally effective, with an expected cure rate of 90%, the trial was designed as a bio-equivalence study (one-sided test) to demonstrate non-inferiority of 3 day therapy, accepting a maximal difference of 10% in favour of 8 day therapy.
Patients, interventions and outcomes
Patients aged 18 years and over, admitted with mild-to-moderatesevere CAP to three academic and six non-academic hospitals in the Netherlands, were eligible for the RCT. In all patients, the diagnosis of CAP was confirmed by chest X-ray. Main exclusion criteria were pregnancy, allergy to the study medication, HIV infection, treatment with effective antibiotic therapy prior to admission and other infections requiring administration of systemic antibiotics.
Patients who had substantially improved after 72 h of treatment were randomly allocated to either 5 day continuation of therapy with oral antibiotics or 5 day placebo treatment. Both patients and researchers assessing the clinical outcomes were blinded to the allocated treatment.
Patients' health status and CAP score, as well as resource utilization, were documented at days 3, 7, 10, 14 and 28 after hospital admission, assuming that clinical and/or economic differences between the two antibiotic strategies should become evident within 4 weeks. The CAP score is a composite score based on respiratory symptoms and general well-being. 9 We documented clinical recovery, treatment success or failure, bacteriological eradication rate and radiological success rate at days 10 and 28.
Costs: methods
We used a bottom-up strategy to prospectively collect data on utilization of healthcare and other resources, parallel to the clinical process. The time horizon of the study was 28 days, including admission and follow-up. We assumed that this horizon would suffice to cover all treatment failures and complications as well as all relevant resource utilization associated with recovery from CAP. The cost-analysis was set up from a societal perspective, implying that costs indirectly generated by healthcare utilization, such as those associated with travel, home care, lost productivity by the absence from paid work, were also taken into account. 10 Costs were classified into three categories:
11,12 direct medical, direct non-medical and indirect costs. Direct medical costs are generated by healthcare utilization and include medication, diagnostic procedures and visits to healthcare providers. Direct non-medical costs reflect utilization of non-healthcare resources generated by the condition and any interventions. In this case, these are mainly costs associated with travel. Indirect costs are associated with lost productivity due to impaired ability to work.
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Costs: volume of resource utilization A prospective registration system was set up and integrated in the clinical record form, documenting inpatient as well as postdischarge healthcare utilization and the absence from work during follow-up for each individual patient. Assessments were made by the research nurse on the day of admission, as well as on days 3, 7, 10, 14 and 28. Documented volumes of inpatient healthcare utilization comprise length of hospital stay, the use of other antibiotic and non-antibiotic therapy and diagnostic assessments (blood gases, microbiology cultures, chest X-ray). During the visit at day 28, the research nurse retrospectively assessed resource utilization since discharge, including length of stay during inpatient re-admissions, outpatient specialist consultations, visits to primary healthcare providers, hours of home care, hours of family care, and days absent from work. Labour status and absence from work have been documented with questions extracted from a standardized questionnaire.
13 Travel distances have been estimated using the number of visits to primary and secondary healthcare providers in combination with average travel distances to these respective providers in the Netherlands.
Costs: unit prices
Estimates of unit costs were based on the authors' real cost calculations (top-down calculation for hospital stay at the pulmonology ward), Dutch pharmaceutical unit cost listings indicating real cost estimates for medications in the Netherlands 14 (for antibiotic therapies), reference prices reflecting estimated average costs for units of healthcare utilization in the Netherlands 12 (for outpatient consultations, visits to primary healthcare providers, home care and travel expenses) and fees as charged to and/or compensated by health insurances 15 (for microbiology cultures, chest X-ray). Productivity loss was estimated using the friction cost approach, whereas informal care was valued using the shadow-pricing method. 12 The friction costs method assumes that costs of lost productivity are limited to the time required to replace someone in the workforce (friction period). The shadow-price approach imputes hypothetical incomes for lost productivity for unpaid activities, such as household and volunteer work. Unit costs have been set at the price level at the mid-point of the study period (2002), and discounted by 3% annually.
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Costs: calculations For each patient, costs per resource were estimated by multiplying the respective volumes of resource use with their corresponding unit prices. Total costs per patient were estimated for the whole 28 day study period, as well as subtotals for the initial hospital admission episode and the post-discharge follow-up. Protocol-costs-associated with the study itselfwere excluded from the analyses. Costs were calculated and reported in euros.
Data on resource utilization were entered and managed in SPSS 12.1, unit costs were entered and elaborated in MS Excel and merging of volumes and unit costs, cost calculations and statistical analyses were carried out in SAS 9.1.
Costs: analysis
All analyses were done according to the intention-to-treat principle. 16 For the two study groups, mean volumes of resource utilization and associated mean costs per patient were estimated. Differences in volumes were tested for significance using a nonparametric Wilcoxon Mann -Whitney test, and the associated differences in mean costs per patient are also reported.
For the total costs per study period (admission and follow-up), the distribution in costs of treatment and follow-up across individual patients was estimated, and reported as means and bootstrap 95% confidence intervals. 17, 18 Owing to the nonnormal distribution of costs, standard ( parametric) confidence intervals do not appropriately reflect the confidence limits. Bootstrap analyses randomly resample the original sample, so that several versions with small variations of the original data set are obtained. On the basis of 500 repeated bootstrap samples, multiple estimates of the mean are used to define a nonparametric 95% confidence interval around the mean.
In sensitivity analyses, the robustness of the findings for uncertainty in the parameters was evaluated for differences in unit costs per day of hospital stay. We evaluated sensitivity for assumptions in absolute unit costs (from 220% to þ20%), calculation method (real costs versus guideline costs) and for neutralizing the difference in unit costs between academic and non-academic settings. Finally, in order to adjust for the relatively large proportion of academic hospitals in our study, we evaluated the impact of a weighted estimate for unit costs, composed to reflect the actual ratio of academic and non-academic hospital beds in the Netherlands.
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Results
Between November 2000 and July 2003, 186 patients were identified, of whom 121 could be randomized at day 3. Two patients had to be excluded because of protocol violations, so 119 patients were included in the evaluation. Demographic and clinical baseline characteristics of these randomized patients were comparable (Table 1) .
Therapeutic success rates at days 10 and 28 were similar for both treatment groups: clinical success rates, symptom recovery and radiological success rates did not differ significantly for both treatment durations. Further details on clinical outcomes have been reported elsewhere.
The results of the cost analysis are summarized in Table 2 , which shows the average resource utilization per patient and associated total and average costs for both treatment groups during admission and follow-up. During admission, costs per patient were predominantly affected by length of hospital stay, and only marginally by medication, imaging diagnostics and laboratory assessments. In the 3 day group, the average hospital stay was on average almost a day shorter (8.8 versus 9.8 days), whereas utilization of other inpatient healthcare resources was comparable. During follow-up, patients in the 3 day group reported on average more visits to primary and outpatient care providers as well as more home and family care and absence from paid work.
During hospital admission, mean total costs per patient were E3721 in the 3 day group versus E3930 in the 8 day group: a difference of E209 in favour of shorter therapy (Table 3) . However, during follow-up, mean total costs per patient were E238 in the 3 day group versus E172 in the 8 day group: a difference of E66 in favour of longer therapy. Overall, average total costs per patient associated with resource utilization during admission and follow-up were estimated as E3959 in the 3 day group versus E4102 in the 8 day group: a difference of E143 in favour of shorter therapy. The difference appeared to be more profound during the admission period (E209 in favour of the 3 day group) but this reduction was partly offset by higher costs generated during follow-up (E66 in favour of the 8 day group).
In sensitivity analyses, in which the impact of different assumptions concerning unit costs for inpatient hospital stay were evaluated, differences between the two strategies in mean total costs per patient varied between 1.7% and 4.9%, but always in favour of 3 day treatment. This percentage difference was found to be systematically associated with these unit costs, as they make up for the majority of costs generated by management of CAP. As a relatively large proportion of patients was admitted to academic hospitals in our study, we adjusted the unit costs to reflect the actual ratio of academic and nonacademic hospital admissions for CAP. The percentage difference in average costs was found to increase to 4.9% in favour of 3 day therapy, whereas the total costs substantially decreased due to lower unit prices of hospital stay for non-academic hospitals.
Discussion
We were able to exclude a significant difference in therapeutic success rates of short (3 days) when compared with standard (8 days) antibiotic therapy in patients hospitalized with a mild-tomoderate -severe CAP. 8 This study demonstrates that resource utilization and associated costs during admission and 28 day follow-up were also comparable.
Although the symptom resolution was comparable in both groups, a minor substitution from inpatient to outpatient services was observed but this substitution was limited in nature. As the costs of treatment of CAP are predominantly generated by the duration of hospitalization, the increase in the use of services of GP and other healthcare professionals is unlikely to offset the cost reduction associated with shorter hospital stay.
Results of this study should be considered within the context of the following potential limitations. First, our findings apply only to patients with a mild-to-moderate -severe CAP who were admitted to a hospital, and substantially improved after 3 days of amoxicillin treatment. As we systematically excluded patients with severe symptoms or a significant amount of pleural fluid as well as non-hospitalized patients, our findings cannot be generalized to these patient groups. The baseline characteristics indicate that our sample can be considered representative for the population of patients with mild-to-moderate -severe CAP.
Our results are based on a relatively small sample size and costs associated with treatment and follow-up of individual patients varied considerably. To demonstrate equivalence in costs would require substantially larger sample sizes. Yet the principal cost drivers, such as the length of hospital stay, can be expected to follow clinical outcomes. Because major differences in clinical outpoints have been demonstrated to be statistically implausible, substantial economic differences in favour of longer treatment are equally unlikely. Additional trials will have to confirm the non-inferiority in clinical and economic outcomes of a shorter duration of treatment in adults with mild-tomoderate -severe CAP who have substantially improved after 3 days of treatment. When physicians may have more confidence in the bio-equivalence of shorter antibiotic regimens, they may be more inclined to discharge patients with sufficient symptom resolution, thereby further contributing to the cost-effectiveness of this treatment strategy.
As costs associated with units of resource utilization are known to vary considerably across countries and healthcare systems, the estimated figures for the Netherlands may not be directly generalizable to other countries. To extrapolate our results to other settings, locally estimated unit costs could be used to valuate volumes of resource utilization reported in this study.
Our study was not designed as a full evaluation of shorter duration of therapy at a societal level. In order to conclusively recommend adjustment of current standards, a full evaluation should address all relevant consequences from a societal perspective. A relevant additional outcome to be considered for societal evaluations of antibiotic strategies to combat infectious pathogens are the consequences of treatment on development of antibiotic resistance. Patients infected with resistant strains require more expensive antibiotic options and generate more costs associated with treatment failures and associated inpatient and outpatient healthcare utilization. 2 The development of antibiotic resistance has been demonstrated to be associated with the amount of antibiotic consumption. 20 Shortening the duration of therapy may lead to less selection of resistant microorganisms. 21 Without being conclusive, our findings add to the evidence that shorter duration of antibiotic therapy can contribute to a more efficient use of antibiotics in terms of the development of resistance and associated costs at a societal level.
